



Objective:

To provide an evidence-based approach to the diagnosis and management of patients presenting with superficial vein thrombosis (SVT).

Background:

Superficial thrombophlebitis or superficial vein thrombosis (SVT)* results from thrombus formation in a superficial vein with associated inflammation of the vessel wall. SVT is most often observed in the lower extremities, with greater saphenous vein (GSV) involvement in 60-80% of affected individuals. SVT is 6-fold more common than deep vein thrombosis (DVT) or pulmonary embolism (PE) with a yearly incidence rate of 0.64%.

It is important to note that SVT is different from thrombus within the superficial femoral vein, which is a deep vein and requires the same approach to management as deep vein thrombosis (DVT) in other deep veins. To avoid confusion, many have abandoned the name superficial femoral vein in favor of femoral vein.

Risk factors for SVT are similar to those for DVT and PE and include active malignancy or cancer therapy, surgery, venous procedures, trauma/injury, immobilization, obesity, estrogen use/pregnancy (particularly in the first month postpartum), a personal or family history of venous thromboembolism (VTE), and inherited thrombophilia. In addition, SVT often occurs in the presence of varicose veins (present in up to 80% of SVT patients) and, in the upper extremities, is often associated with intravenous catheters. SVT is a risk factor for concomitant and future VTE.

Diagnosis:

At diagnosis, approximately 25% of patients with SVT are found to have concomitant VTE. The diagnosis of SVT can be made clinically, based on the presence of characteristic signs and symptoms including erythema, warmth and tenderness along a palpable cord. Compression ultrasound (CUS) is suggested in most cases to confirm the presence of SVT, rule out DVT, and delineate the length of the thrombus and proximity to the saphenofemoral junction (SFJ) or saphenopopliteal junction (SPJ), where the GSV and small saphenous vein join the deep veins, respectively. Details regarding these parameters should be sought from the radiologist when not included in the ultrasound report.

CUS should be performed in the majority of patients with clinically diagnosed SVT, particularly those with symptoms above the knee or located close to the popliteal fossa, in those with symptoms suggestive of DVT and in patients with VTE risk factors. Patients with below the knee SVT restricted to a varicose vein without additional VTE risk factors may not require CUS assessment.

Treatment of SVT:

General measures:

- As approximately 4% of patients with SVT will have a concomitant symptomatic PE, all patients should be assessed for a history of PE symptoms (e.g. dyspnea, pleuritic chest pain, hemoptysis) and investigated accordingly [See Clinical Guide [Pulmonary Embolism \(PE\): Diagnosis](#)].
- Patients with upper extremity SVT associated with vein cannulation or IV catheters should be assessed for signs of infection (e.g. fever, purulent discharge at insertion site).
- Patients who are over age 40 with no varicose veins or other obvious risk factors for VTE should have age- and gender-appropriate screening for malignancy. Migratory superficial thrombophlebitis further increases the index of suspicion for malignancy.

Approach to treatment

Once SVT is diagnosed, treatment will depend on whether or not a concomitant DVT is identified and on the extent and most proximal location of the SVT (see **Figure 1** for management algorithm). Antibiotic therapy is generally not indicated unless there are signs of infection.

- Patients in whom a **concomitant DVT** is identified should be managed with **therapeutic anticoagulation** [see Clinical Guide [Deep Vein Thrombosis \(DVT\): Treatment](#)].
- Isolated SVT which extends to **within 3 cm of the SFJ or SPJ** could be associated with a higher risk of progression into the deep venous system, and therefore these patients are often treated with **therapeutic doses of anticoagulation** for 3 months [see Clinical Guide [Deep Vein Thrombosis \(DVT\): Treatment](#)]. However, evidence supporting this practice is not as strong as randomized controlled trials of SVT have all excluded these patients.
- For isolated SVT **≥5 cm in length** located >3 cm from the SFJ, **prophylactic doses of fondaparinux (2.5 mg SC daily) or rivaroxaban (10 mg PO daily) or prophylactic/intermediate doses of LMWH (see Table 1)** for 45 days is recommended. Patients can also receive topical nonsteroidal anti-inflammatory drugs (NSAIDs) and/or compression therapy for symptomatic relief in conjunction with anticoagulation.
- Isolated SVT <5 cm in length located >3 cm from the SFJ/SPJ can be treated with oral or topical NSAIDs, compresses (warm or cool), and elevation for symptomatic relief. Compression stockings of appropriate length and tension can be considered if tolerable and no contraindications exist (e.g. known peripheral arterial disease). If these patients have severe symptoms or risk factors for thrombus extension (prior history of DVT/PE or SVT, cancer, pregnancy, hormonal therapy, recent surgery or trauma), treatment with prophylactic doses of fondaparinux (2.5 mg SC daily), prophylactic doses of rivaroxaban (10 mg PO daily) or prophylactic/intermediate doses of LMWH (**see Table 1**) for up to 45 days can be considered.
- SVT associated with IV cannulation is not generally treated with anticoagulation. Supportive measures such as warm compresses and topical NSAIDs can be considered for symptom relief.

Role of ultrasound in management of SVT

Ultrasound imaging of the affected leg is used to exclude/confirm extension into the deep veins. It is not used to determine duration of anticoagulation if a patient is started on anticoagulation for SVT (see Table 1). Duration of anticoagulation is based on the time frames evaluated in clinical trials (i.e., 45 days), on

resolution of evidence of acute inflammation (e.g. warmth, erythema, tenderness on palpation), and risk factors for recurrence (e.g. active cancer, current pregnancy). Please note that brownish discolouration or a palpable lump that is not tender over a superficial vein is not considered acute inflammation and does not indicate need for treatment.

Special Populations:

Malignancy


No randomised studies have assessed duration of anticoagulation in patients who develop SVT in the setting of active cancer. Given that it is a strong risk factor for extension into the deep veins, most cancer patients with SVT are generally offered treatment with anticoagulation for a minimum of 45 days with one of the agents in **Table 1** (assuming the risk of bleeding on anticoagulation is low). Extension beyond 45 days should be individually based on the severity of initial presentation, persistence of symptoms, and concern about recurrence.

Pregnancy

No randomized studies have assessed the management of SVT during pregnancy. Guideline recommendations differ and include prophylactic or intermediate doses of LMWH for a fixed period (1 to 6 weeks) or throughout pregnancy and the postpartum period in pregnant women with SVT that is bilateral, symptomatic, ≤ 3 cm from the deep venous system or ≥ 5 cm in length. In a Danish nationwide cohort study, antepartum SVT not treated with anticoagulation was associated with a 10.4% risk of subsequent VTE in the same pregnancy. If no treatment is administered, close clinical follow-up and repeat CUS is recommended within 7 to 10 days. Warfarin and DOACs are contraindicated in pregnancy as these medications can cross the placenta. [see **Clinical Guide [Pregnancy: Venous Thromboembolism Treatment](#)**].

Pediatrics

Data regarding the management of SVT in this population are very limited. If possible, pediatric hematologists with experience in thromboembolism should manage children with or at risk for SVT. When this is not possible, a combination of a neonatologist/pediatrician and an adult hematologist, supported by consultation with an experienced pediatric hematologist, should manage these children.

Figure 1: Approach to management of SVT

* Prophylactic/intermediate dosing anticoagulation is reasonable for severe symptoms or with risk factors. If not treating or if using topical NSAIDs, monitor for extension with repeat U/S 7 to 10 days later. The goal of U/S is to rule out extension into the deep veins, not to confirm resolution of thrombus which may take weeks or be present indefinitely.

DVT, deep vein thrombosis; NSAID, non-steroidal anti-inflammatory; LMWH, low molecular weight heparin

Table 1: Treatment Options for SVT*

Drug class	Suggested dosing	Duration of treatment
LMWH**	Dalteparin 5,000-10,000 units SC daily Enoxaparin 40-80 mg SC daily Tinzaparin 4,500-10,000 units SC daily	45 days
Fondaparinux**	2.5 mg SC daily	45 days
Rivaroxaban**	10 mg PO daily	45 days
Oral NSAIDs	Ibuprofen 400 mg PO TID Naproxen 500 mg PO BID	7-14 days
Topical NSAIDs	Topical diclofenac [Voltaren Emugel®] apply 2 to 4 g to affected area 3 or 4 times daily	7-14 days

* Patients should be treated with therapeutic anticoagulation if they have concomitant DVT and/or have isolated SVT within 3cm of the deep system (i.e. SFJ, SPJ). Choice of anticoagulant will be determined based on local availability, physician familiarity, and patient coverage, values, and preferences.

**Assuming risk of bleeding on anticoagulant therapy is low.

Recurrent SVT

Patients with SVT in the context of varicose veins have a high risk of recurrence. Unfortunately, to date, no clinical studies have evaluated the efficacy of long-term anticoagulation for prevention of recurrent SVT. If symptoms of acute inflammation recur in a patient with a history of SVT, an ultrasound should be repeated to rule out extension into the deep veins and consideration should be given for short-term anticoagulation as per Table 1. All patients with SVT should be advised of the risk of recurrence as well as the signs and symptoms of DVT and PE.

Other Relevant Thrombosis Canada Clinical Guides:

- [Deep vein thrombosis \(DVT\): Diagnosis](#)
- [Deep vein thrombosis \(DVT\): Treatment](#)
- [Pulmonary embolism \(PE\): Diagnosis](#)
- [Pregnancy: Venous Thromboembolism Treatment](#)
- [Rivaroxaban \(Xarelto®\)](#)
- [Unfractionated Heparin, Low Molecular Weight Heparin and Fondaparinux](#)

Help sustain trusted thrombosis guidance.

Ongoing expert review and regular updates ensure Thrombosis Canada's clinical guides remain current and reliable. Your support helps protect the quality and continuity of these resources for clinicians nationwide.

<https://thrombosiscanada.ca/hcp/Donate-2>



References:

Bates S, et al. American Society of Hematology (ASH) guidelines for management of venous thromboembolism in the context of pregnancy. Blood Advances 2018;2:3317-3359.

Beyer-Westendorf J, et al. SURPRISE investigators. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017;4(3):e105-e113.

Decousus H, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. New Engl J Med 2010;363(13):1222-1232.

Decousus H, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Annals Inter Med 2010;152(4):218-224.

Di Minno MN, et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2016;14:964-972.

Di Nisio M, et al. Treatment of superficial vein thrombosis: Recent advances, unmet needs, and future directions. Healthcare 2024;12(15):1517.

Di Nisio M, et al. Treatment of lower extremity superficial thrombophlebitis. JAMA 2018;320(22):2367–2368.

Duffett L, et al. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thrombosis Haemostasis 2019;119:479-489.

Frappe P, et al. Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study. J Thromb Haemost 2014;12:831-838.

Stevens S, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest 2021;160(6):2247-2259.

Van Langevelde K, et al. Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: Results from the MEGA study. Blood 2011;118(15):4239-4241.

Wiegers HMG, et al. Incidence and prognosis of superficial vein thrombosis during pregnancy and the postpartum period: a Danish nationwide cohort study. Lancet Haematol 2023;10(5):e359-e366.

Date of version: 29March2025

Please note that the information contained herein is not to be interpreted as an alternative to medical advice from your doctor or other professional healthcare provider. If you have any specific questions about any medical matter, you should consult your doctor or other professional healthcare providers, and as such you should never delay seeking medical advice, disregard medical advice or discontinue medical treatment because of the information contained herein.